Lou Gehrig's Disease News and Research

RSS
Lou Gehrig's Disease or Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder characterized by progressive degeneration of motor neuron cells in the spinal cord and brain, which ultimately results in paralysis and death. The disease takes its less-scientific name from Lou Gehrig, a baseball player with the New York Yankees in the late 1920s and 1930s, who was forced to retire in 1939 as a result of the loss of motor control caused by the disease.

In 1991, a team of researchers linked familial ALS to chromosome 21. Two years later, the SOD1 gene was identified as being associated with many cases of familial ALS. The enzyme coded for by SOD1 carries out a very important function in cells: it removes dangerous superoxide radicals by converting them into non-harmful substances. Defects in the action of this enzyme mean that the superoxide radicals attack cells from the inside, causing their death. Several different mutations in this enzyme all result in ALS, making the exact molecular cause of the disease difficult to ascertain.

Recent research has suggested that treatment with drugs called antioxidants may benefit ALS patients. However, since the molecular genetics of the disease are still unclear, a significant amount of research is still required to design other promising treatments for ALS.
Researchers explain how 'viral' agents of neurological diseases ended up in our DNA

Researchers explain how 'viral' agents of neurological diseases ended up in our DNA

Copper compound with potential as therapy for ALS shows further promise

Copper compound with potential as therapy for ALS shows further promise

Researchers determine atomic interactions that stabilize phase-changing proteins

Researchers determine atomic interactions that stabilize phase-changing proteins

Protein Clumps In ALS Neurons Provide Potential Target For New Therapies

Protein Clumps In ALS Neurons Provide Potential Target For New Therapies

Anti-aging protein hormone Klotho shown to be neuroprotective in ALS model

Anti-aging protein hormone Klotho shown to be neuroprotective in ALS model

Study finds link between high BMI and lower risk of ALS

Study finds link between high BMI and lower risk of ALS

UTA professor awarded $2.88 million for novel research on Lou Gehrig's disease

UTA professor awarded $2.88 million for novel research on Lou Gehrig's disease

Human iPSCs make more tiny 'cargo packets' to deliver cellular aging therapies

Human iPSCs make more tiny 'cargo packets' to deliver cellular aging therapies

Researchers uncover potential clue to halt destruction of nerve cells in people with ALS

Researchers uncover potential clue to halt destruction of nerve cells in people with ALS

Biochemical switches could be triggered to treat pathology of IBM, ALS and FTD

Biochemical switches could be triggered to treat pathology of IBM, ALS and FTD

Scientists solve mystery surrounding common genetic cause of ALS

Scientists solve mystery surrounding common genetic cause of ALS

UTA nursing professor receives $6.575 million to attack musculoskeletal diseases

UTA nursing professor receives $6.575 million to attack musculoskeletal diseases

Pesticides, other environmental pollutants advance progression of ALS

Pesticides, other environmental pollutants advance progression of ALS

Peripheral nerve injury can trigger the onset and spread of ALS, shows study

Peripheral nerve injury can trigger the onset and spread of ALS, shows study

BGU develops new AI platform for monitoring and predicting ALS progression

BGU develops new AI platform for monitoring and predicting ALS progression

OHSU paper recommends feeding tubes to be excluded from POLST

OHSU paper recommends feeding tubes to be excluded from POLST

New drug could significantly slow progression of ALS, shows research

New drug could significantly slow progression of ALS, shows research

New compound blocks genetic cause of familial ALS and frontotemporal dementia

New compound blocks genetic cause of familial ALS and frontotemporal dementia

Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows

Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows

Mount Sinai researcher awarded $2.5 million to advance understanding of neurodegenerative diseases

Mount Sinai researcher awarded $2.5 million to advance understanding of neurodegenerative diseases